^
    Apply
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (NCT04570839)
    Phase 1/2
    Compugen Ltd
    Completed
    Last update posted :
    07/18/2024
    Initiation :
    08/31/2020
    Primary completion :
    05/15/2024
    Completion :
    05/15/2024
    TNFRSF9
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (NCT02913313)
    Phase 1/2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    04/03/2024
    Initiation :
    11/30/2016
    Primary completion :
    01/25/2024
    Completion :
    01/25/2024
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)